What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
IGF-1 Ec splice-variant peptide
Vialdyne buyer fit
This Vialdyne page is intentionally positioned for compounding-pharmacy, clinic, and regulated procurement teams evaluating MGF (Mechano Growth Factor). It is not the broad research monograph for this SKU; the page emphasizes buyer qualification, release testing, documentation depth, and whether the active fits the destination-market workflow before pricing.
Overview
MGF (Mechano Growth Factor) is a 24-residue C-terminal peptide. The peptide is derived from the Ec splice variant of the IGF-1 gene, an alternative splicing outcome that yields an E-domain extension distinct from the more frequently studied IGF-1Ea form. In skeletal muscle, mechanical loading and exercise stress preferentially upregulate the Ec splice variant, the source of the 'Mechano Growth Factor' name. Pharmacologically, current models suggest the C-terminal E-peptide engages a receptor that is not the classical IGF-1 receptor, and that this signalling axis drives satellite-cell proliferation in muscle-repair studies, the substrate of MGF's research interest and the rationale for stocking it in the catalogue alongside the related IGF-1 LR3 SKU. For research-lab buyers, Vialdyne releases unmodified MGF (the synthetic C-terminal E-peptide alone, not the full IGF-1 Ec protein) as a lyophilised 2 mg vial against a ≥99.0% main-peak HPLC specification. Plasma half-life is exceptionally short, on the minutes scale, which is why PEGylated MGF tends to be the more commercially deployed form for in vivo research workflows. Unmodified MGF fits cell-culture biochemical studies where the short half-life is not a limitation because the dose enters a defined system directly. LC-MS/MS sequence verification is the recommended qualification add-on at first-time pharmacy onboarding: because the MGF sequence partially overlaps with IGF-1, positive identity confirmation across supplier sources needs explicit tandem-MS sequencing rather than relying on intact-mass spec alone to rule out IGF-1-derived contaminating species.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Sterile-filled vials are available with the full release packet (sterility, endotoxin, CCI); loose lyophilized powder ships with sequence verification.
Primary buyer fit: academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for MGF (Mechano Growth Factor), every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
Browse all published COAsRegulatory note
Across suppliers, the CAS assigned to unmodified MGF is not consistently standardized; use the batch COA to confirm both the sequence and PEG status (unmodified MGF should carry no PEG if any).
Selected literature
Frequently asked questions
Two related but functionally distinct molecules. IGF-1 (Insulin-like Growth Factor 1) is the full-length 70-residue mature growth factor expressed primarily by the liver in response to growth hormone signalling. MGF (Mechano Growth Factor) is a 24-residue C-terminal peptide derived from the IGF-1 Ec splice variant of the IGF-1 gene, preferentially induced in skeletal muscle by mechanical loading. The C-terminal E-peptide is what distinguishes MGF from the more commonly characterised IGF-1Ea form, and it is hypothesised to act through a receptor distinct from the classical IGF-1 receptor. Practically: IGF-1 LR3 is the right tool for IGF-1-receptor pharmacology research, while MGF is the right tool for E-peptide-specific satellite-cell signalling work driving muscle repair.
PK economics. Unmodified MGF has a plasma half-life measured in minutes, which is biologically appropriate, the molecule is meant to function as a local autocrine/paracrine signal in muscle tissue, not as a systemic hormone, but it makes any in vivo workflow that requires sustained exposure across hours or days operationally impractical. PEG-MGF (the PEGylated form) was developed specifically to extend functional half-life into a usable range for in vivo dosing, and is the more commonly chosen form for that context. Unmodified MGF fits cell-culture and short-duration biochemical assays where the minutes-scale stability is sufficient and the experimental design works around it.
Related peptides
